BioLife Wins Oral Peptide Delivery Patent as GLP-1 Pills Race On

BioLife, a Paris-based drug delivery company, said on Sept. 10 that the U.S. Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for an effervescent tablet designed to carry peptide drugs, including GLP-1 medicines such as semaglutide, through the digestive tract intact. The grant is a bet on the field’s hardest unsolved problem: peptide medicines work when injected, but very few survive being swallowed.

What BioLife says it patented

The technology, developed internally as OralMatrix, is a dissolvable effervescent tablet that creates what the company calls a gastric buffer, a temporary environment intended to shield the peptide as it passes through the stomach and small intestine. BioLife frames that as a departure from two established strategies: protective coatings, and absorption-enhancing excipients such as the salcaprozate sodium (SNAC) used in the first oral GLP-1.

The claims are unusually broad for a delivery platform. They extend across the GLP-1 class, covering semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide, with protection running into 2042 and further applications pending internationally.

The evidence attached to the announcement is preclinical. BioLife says its studies produced measurable systemic semaglutide exposure after oral administration, which it describes as in vivo proof of concept. The company states plainly that the technology is in development and is not approved for the treatment of any disease.

“GLP-1 medicines have changed how obesity and metabolic disease are treated, but we still need better oral options,” said Dr. Farid Bennis, BioLife’s founder and the named inventor on the patent. He called the grant “much more than protection for a formulation,” pointing to a programme that spans nearly two decades of oral peptide research, including human studies of oral insulin formulations. Bennis also chairs Laprophan Group, a pharmaceutical manufacturer founded in 1949.

Why an oral peptide is so hard to build

Peptides are large molecules, and the gut is built to break them down. Digestive enzymes cut the chains apart, and the intestinal lining is stingy about letting molecules of that size cross into the bloodstream. A formulation has to do two things at once: keep the peptide intact long enough to reach an absorption site, then release it in a form that actually gets through.

The approved oral GLP-1 peptides show how narrow that window is. Rybelsus, the first oral GLP-1, was approved in 2019 and is co-formulated with SNAC. According to the FDA-approved label, semaglutide’s estimated absolute bioavailability after oral administration is roughly 0.4% to 1% in the original formulation, and absorption occurs predominantly in the stomach. That is why the label instructs patients to take the tablet on an empty stomach with no more than four ounces of water and then wait at least 30 minutes before food, drink, or other oral medicines. The Wegovy pill, oral semaglutide 25 mg, was approved on Dec. 22, 2025 as the first oral GLP-1 for weight management in the United States, posting 16.6% mean weight loss at 64 weeks in the OASIS 4 trial among patients who stayed on treatment.

The alternative is to stop using peptides altogether. Eli Lilly’s Foundayo (orforglipron), approved April 1, 2026, is an oral small-molecule GLP-1 that can be taken at any time of day without food or water restrictions. Our comparison of approved oral GLP-1s covers the efficacy, dosing and cost landscape in detail.

That contrast is the commercial logic behind BioLife’s filing. Novo Nordisk scaled a peptide up with an absorption enhancer and accepted the fasting rules. Lilly sidestepped peptides on the oral side entirely. A platform that removes both the administration constraints and the dose penalty from peptide pills would be worth more than any single product, which is why a patent claim, not a clinical result, is the news here.

What would actually prove the technology

Preclinical exposure is a starting line, not a finish line. Drug Target Review’s report on the grant noted that its immediate significance is intellectual property protection “rather than evidence of a new approved medicine,” and that the open questions are whether the approach delivers consistent exposure across different peptide molecules, doses and patient populations, and whether that exposure produces a predictable therapeutic response.

For readers tracking the gap between marketing and medicine, the distinction matters. The grey-market peptide trade that FDA warning letters have targeted is a separate problem: unapproved compounds sold as consumer wellness products with no human safety data. BioLife’s patent sits at the opposite end of the market, where a formulation problem is being attacked inside FDA-regulated drug development, with years of clinical work still ahead of it.

What to watch

Three developments would show whether the approach amounts to more than a filing:

• Whether BioLife moves the formulation into human clinical studies, or licenses the platform to a developer that already owns a GLP-1 asset.
• Whether the gastric-buffer mechanism holds up across peptide classes beyond the GLP-1s, where the company says the opportunity extends.
• Whether regulators see a viable pathway for a delivery technology that changes absorption without changing the active molecule.

The peptide synthesis market is being rebuilt around demand that assumes these delivery problems get solved. BioLife’s patent is now an enforceable claim on one way to solve them, unproven in humans, and valid until 2042.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.